Pain Crises New Main Goal in Ongoing Ardent Trial of IMR-687

Pain Crises New Main Goal in Ongoing Ardent Trial of IMR-687

314195

Pain Crises New Main Goal in Ongoing Ardent Trial of IMR-687

Imara has announced that it will change the main goal of its ongoing Phase 2b Ardent trial, which is assessing the safety and efficacy of IMR-687 for the treatment of sickle cell disease (SCD). The trial’s new main goal is the annual rate of vaso-occlusive crises (VOCs) — painful crises resulting from blood vessel blockage by “sickle-shaped” red blood cells. This had been a key secondary goal. This alteration followed a recommendation made by the U.S.…

You must be logged in to read/download the full post.